A generic alternative indicated for HIV. This formulation supports the suppression of viral replication, facilitating stable long-term viral load management.
Utilized to manage HIV-1 infections by addressing viral replication to alleviate immune system strain and support long-term health in infected patients.
Mechanism of Action
Dolutegravir blocks the HIV integrase enzyme, which the virus uses to insert its genetic material into human DNA. By preventing this step, the drug stops the virus from replicating inside the body's immune cells.
Route of Administration
Oral
Onset Time
Variable; viral load decreases in weeks
Duration
24 hours
Contraindications
Hypersensitivity to dolutegravir, Concurrent use with dofetilide
Severe Adverse Events
Severe liver toxicity, Severe allergic reactions, Depression, Neural tube defects (potential fetal warning)
Common Side Effects
Headache, Mild fatigue
Uncommon Side Effects
Insomnia, Nausea, Diarrhea, Dizziness
Drug Interactions
Dofetilide, Metformin, Rifampin, Calcium/Iron supplements, St. John's Wort
Pregnancy Safety Warnings
Use with caution; earlier warnings for neural tube defects exist.
Age Restrictions
Approved for adults and children over 3kg (specific formulations).
Information for Dolutegravir is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
